Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Karyopharm Therapeutics stock | $5.31

Learn how to easily invest in Karyopharm Therapeutics stock.

Karyopharm Therapeutics Inc is a biotechnology business based in the US. Karyopharm Therapeutics shares (KPTI) are listed on the NASDAQ and all prices are listed in US Dollars. Karyopharm Therapeutics employs 432 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Karyopharm Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KPTI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Karyopharm Therapeutics stock price (NASDAQ: KPTI)

Use our graph to track the performance of KPTI stocks over time.

Karyopharm Therapeutics shares at a glance

Information last updated 2021-10-17.
Latest market close$5.31
52-week range$4.42 - $18.00
50-day moving average $5.87
200-day moving average $8.11
Wall St. target price$15.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.80

Buy Karyopharm Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Karyopharm Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Karyopharm Therapeutics price performance over time

Historical closes compared with the close of $5.31 from 2021-10-20

1 week (2021-10-15) -5.01%
1 month (2021-09-22) -13.09%
3 months (2021-07-22) -41.20%
6 months (2021-04-22) -44.80%
1 year (2020-10-22) -65.59%
2 years (2019-10-22) -53.30%
3 years (2018-10-22) 11.99
5 years (2016-10-21) 8.59

Karyopharm Therapeutics financials

Revenue TTM $102.3 million
Gross profit TTM $-45,433,000
Return on assets TTM -34.8%
Return on equity TTM -891.05%
Profit margin -203.25%
Book value $0.68
Market capitalisation $422 million

TTM: trailing 12 months

Shorting Karyopharm Therapeutics shares

There are currently 14.4 million Karyopharm Therapeutics shares held short by investors – that's known as Karyopharm Therapeutics's "short interest". This figure is 9.5% up from 13.2 million last month.

There are a few different ways that this level of interest in shorting Karyopharm Therapeutics shares can be evaluated.

Karyopharm Therapeutics's "short interest ratio" (SIR)

Karyopharm Therapeutics's "short interest ratio" (SIR) is the quantity of Karyopharm Therapeutics shares currently shorted divided by the average quantity of Karyopharm Therapeutics shares traded daily (recently around 1.3 million). Karyopharm Therapeutics's SIR currently stands at 10.86. In other words for every 100,000 Karyopharm Therapeutics shares traded daily on the market, roughly 10860 shares are currently held short.

However Karyopharm Therapeutics's short interest can also be evaluated against the total number of Karyopharm Therapeutics shares, or, against the total number of tradable Karyopharm Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Karyopharm Therapeutics's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Karyopharm Therapeutics shares in existence, roughly 190 shares are currently held short) or 0.2453% of the tradable shares (for every 100,000 tradable Karyopharm Therapeutics shares, roughly 245 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Karyopharm Therapeutics.

Find out more about how you can short Karyopharm Therapeutics stock.

Karyopharm Therapeutics share dividends

We're not expecting Karyopharm Therapeutics to pay a dividend over the next 12 months.

Karyopharm Therapeutics share price volatility

Over the last 12 months, Karyopharm Therapeutics's shares have ranged in value from as little as $4.42 up to $18. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Karyopharm Therapeutics's is 0.1899. This would suggest that Karyopharm Therapeutics's shares are less volatile than average (for this exchange).

Karyopharm Therapeutics overview

Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company's lead compound, XPOVIO (selinexor), is approved in the U. S. in various hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. Its NEXPOVIO (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission.

Frequently asked questions

What percentage of Karyopharm Therapeutics is owned by insiders or institutions?
Currently 9.781% of Karyopharm Therapeutics shares are held by insiders and 82.583% by institutions.
How many people work for Karyopharm Therapeutics?
Latest data suggests 432 work at Karyopharm Therapeutics.
When does the fiscal year end for Karyopharm Therapeutics?
Karyopharm Therapeutics's fiscal year ends in December.
Where is Karyopharm Therapeutics based?
Karyopharm Therapeutics's address is: 85 Wells Avenue, Newton, MA, United States, 02459
What is Karyopharm Therapeutics's ISIN number?
Karyopharm Therapeutics's international securities identification number is: US48576U1060
What is Karyopharm Therapeutics's CUSIP number?
Karyopharm Therapeutics's Committee on Uniform Securities Identification Procedures number is: 48576U106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site